CompletedInterventionalPhase 2Updated Feb 18, 2021
AGN-199201 for the Treatment of Erythema With Rosacea | NCT01735201 | Trialant
CompletedInterventionalPhase 2Updated Nov 18, 2019
AGN-199201 for the Treatment of Erythema With Rosacea
ClinicalTrials.gov ID
NCT01735201
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
357Actual
Last Update Posted
Nov 18, 2019Actual
Start Date
Dec 2012
Primary Completion Date
May 2013Actual
Completion Date
Jun 2013Actual
Brief Summary
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
Rosacea
Erythema
AGN-199201 Dose A
AGN-199201 Dose B
AGN-199201 Dose C
AGN-199201 Vehicle
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Redness of the skin caused by rosacea
Exclusion Criteria:
≥3 inflammatory lesions
Laser light-source or other energy based therapy in the last 6 months
Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days